Guizhou Bailing announced that it signed the "Technology Development (Cooperation) Contract" with Wuhan Municipal Hospital of Traditional Chinese Medicine, and the two sides intend to jointly participate in the research and development of the medical institution preparation "Sugar Ning Tongluo Tablets" project.
Guizhou Bailing 2021 interim report shows that the company's main revenue was 1.273 billion yuan, down 0.55% year-on-year; net profit attributable to the mother was 81.5042 million yuan, down 24.94% year-on-year; deduction of non-net profit was 72.2203 million yuan, down 23.73% year-on-year; among them, in the second quarter of 2021, the company's single-quarter main revenue was 520 million yuan, up 3.38% year-on-year; single-quarter net profit attributable to the mother was 19.2481 million yuan, down 20.42% year-on-year In the single quarter, the non-net profit was 15.9271 million yuan, up 51.71% year-on-year; the debt ratio was 39.44%, the investment income was 5.8781 million yuan, the financial expense was 45.655 million yuan, and the gross profit margin was 60.06%.
The chairman of the company is Jiang Wei. Mr. Jiang Wei: born in 1961, Chinese nationality, no right of abode abroad, bachelor degree, senior engineer, graduated from the Department of Pharmacy of Guiyang University of Traditional Chinese Medicine in 1982, university culture, senior engineer. He has successively served as the director of Anshun Pharmaceutical Factory, the chairman of Guizhou Bailing Pharmaceutical Co., Ltd., the chairman of Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd., and the chairman of Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. He has been the Chairman of the Board of Directors of the Company since December 25, 2007.